Zobrazeno 1 - 10
of 192
pro vyhledávání: '"HER2-negative breast cancer"'
Publikováno v:
Cancer Management and Research, Vol Volume 16, Pp 691-701 (2024)
Lianru Zhang,1,2,* Jie Xiao,1,2,* Yishan Li,1,2,* Baorui Liu,1,2 Li Xie1,2 1The Comprehensive Cancer Center of Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, People’s Republic of China;
Externí odkaz:
https://doaj.org/article/371d7cbae2394cc78d1f6c65e3a366f4
Autor:
Sofia Schaeffer, Christian Lutz, Michael Dobbie, Luigi M. Terracciano, Matthias Matter, Jürg Vosbeck, Markus H. Heim, Christine Bernsmeier
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundIdiosyncratic drug-induced liver injury (DILI) is a rare, unpredictable hepatic adverse event and the most common cause of acute liver failure in Europe and the US. Ribociclib is a potent Cyclin-dependent kinase 4 and 6 (CDK4/6)-inhibitor a
Externí odkaz:
https://doaj.org/article/89aa1a97aca843faafac9d5b4d159c2c
Autor:
Board Editorial
Publikováno v:
Современная онкология, Vol 24, Iss 1, Pp 24-29 (2022)
The Satellite Symposium of Novartis Pharma was held on January 28th,2022, within the framework of the RUSSCO Big Conference "Breast Cancer". It was dedicated to the diagnostics and treatment of patients with hormone receptor-positive HER2-negative ad
Externí odkaz:
https://doaj.org/article/bff9eb124e93484182cd3e91851d4504
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundIn vivo and in vitro experiments have demonstrated that diagnostic ultrasound combined with microbubbles (USMB) can enhance tumor chemotherapy, but few clinical studies have explored the effect of USMB in human HER2-negative breast cancer.
Externí odkaz:
https://doaj.org/article/e58ee07673474009ad1d38b44b230883
Publikováno v:
Cancer Medicine, Vol 10, Iss 13, Pp 4658-4674 (2021)
Abstract Aims Prognosis of patients for human epidermal growth factor receptor 2 (HER2)‐negative breast cancer post neoadjuvant chemotherapy is not well understood. The aim of this study was to develop a novel pharmacophore‐based signature to bet
Externí odkaz:
https://doaj.org/article/894293fc990c481aaae324baa300746b
Autor:
Wei Wu, Jiewen Chen, Heran Deng, Liang Jin, Zhanghai He, Nanyan Rao, Yan Nie, Yandan Yao, Yaping Yang, Fengxi Su, Jieqiong Liu
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background Here we evaluated the feasibility, efficacy, tolerability, and treatment-mediated immune modulation of neoadjuvant everolimus plus letrozole versus chemotherapy in treating postmenopausal patients with ER-positive, HER2-negative b
Externí odkaz:
https://doaj.org/article/6177ffceb2014b5b9cae1e9c928e4cd6
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-10 (2021)
Abstract Background There is currently no clinical trial data regarding the efficacy of everolimus exemestane (EE) following prior treatment with CDK4/6 inhibitors (CDK4/6i). This study assesses the use and efficacy of everolimus exemestane in patien
Externí odkaz:
https://doaj.org/article/149b6b346a3a4fc299d9d8918e091ff3
Autor:
Miguel Quintela-Fandino, Esther Holgado, Luis Manso, Serafin Morales, Begoña Bermejo, Ramon Colomer, Juan V. Apala, Raquel Blanco, Manuel Muñoz, Eduardo Caleiras, Vega Iranzo, Mario Martinez, Orlando Dominguez, Javier Hornedo, Lucia Gonzalez-Cortijo, Javier Cortes, Ariadna Gasol Cudos, Diego Malon, Antonio Lopez-Alonso, María C. Moreno-Ortíz, Silvana Mouron, Santos Mañes
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-14 (2020)
Abstract Background Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore the efficacy and b
Externí odkaz:
https://doaj.org/article/3f6add655fbe4b0d92de37dd9a97fca3
Autor:
Mei Yang, Yanhui Fan, Zhi-Yong Wu, Jin Gu, Zhendong Feng, Qiangzu Zhang, Shunhua Han, Zhonghai Zhang, Xu Li, Yi-Ching Hsueh, Yanxiang Ni, Xiaoling Li, Jieqing Li, Meixia Hu, Weiping Li, Hongfei Gao, Ciqiu Yang, Chunming Zhang, Liulu Zhang, Teng Zhu, Minyi Cheng, Fei Ji, Juntao Xu, Hening Cui, Guangming Tan, Michael Q. Zhang, Changhong Liang, Zaiyi Liu, You-Qiang Song, Gang Niu, Kun Wang
Publikováno v:
EBioMedicine, Vol 69, Iss , Pp 103446- (2021)
Background: Breast cancers can be divided into HER2-negative and HER2-positive subtypes according to different status of HER2 gene. Despite extensive studies connecting germline mutations with possible risk of HER2-negative breast cancer, the main ca
Externí odkaz:
https://doaj.org/article/e0a93f66f07e4e4c8bc8d205d5087231
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.